

Re: Summary of Formulary Changes Effective June 30, 2025

Dear Health Partner,

We are dedicated to partnering with you in the most effective way to manage our members' care. CareSource routinely reviews medications available on the Preferred Drug List (PDL). We encourage you to actively work with your CareSource patients in advance of the effective date above to ensure a smooth transition.

THE FOLLOWING MEDICATIONS HAVE A CHANGE IN STATUS EFFECTIVE JUNE 30th. 2025.

Brand Name	Generic Name	Strength(s)	Notes if Applicable
Orlynvah	sulopenem etzadroxil and probenecid	All strengths of tablet	Quantity limit applied
Cuvrior	trientene tetrahydrochloride	All strengths of tablet	Quantity limit applied
Attruby	acoramidis hydrochloride	All strengths of tablet	Quantity limit applied
Crenessity	crinecerfont	All strengths of capsule and solution	Quantity limit applied
Xermelo	telotristat etiprate	All strengths of tablet	Quantity limit applied
Brixadi	Buprenorphine	All strengths of solution	Prior authorization update
Sublocade	Buprenorphine	All strengths of solution	Prior authorization update

What you should know

We know patient care is of the utmost importance to you. We are notifying our members of this change to help ensure their treatment plan is maintained. We have asked our members to contact their prescriber if they have questions.

Additional Resources

For the most up-to-date information, please utilize the <u>formulary search tools</u> online. To access the complete formulary, visit the Provider Pharmacy pages at CareSource.com. You may find your patient's plan formulary by clicking on:

- Your patient's CareSource plan
- Tools & Resources
- Drug Formulary

We recognize each patient is unique and we apprecial a successful transition. We are here to help you with Provider Services at 1-844-607-2831. We are open Na.m. ET to 7 p.m./8 p.m.ET. Thank you for being a Carreland of the control	any questions. Call CareSource Monday through Friday, 7 a.m. CT/8
Sincerely,	
CareSource	
IN-MED-P-3685888-V.1: Issue Date: 4/29/2025	OMPP Approved: 4/29/2025